KIF28P: A Potential Drug Target and Biomarker (G100130097)

Target Name: KIF28P

NCBI ID: G100130097

KIF28P

KIF28P: A Potential Drug Target and Biomarker

Kallikrein-related peptidases (KAPs), also known as kallikrein-proteases, are a family of enzymes that regulate various physiological processes in the body, including blood clotting, tissue repair, and inflammation. KIF28P is a member of this family and has been identified as a potential drug target and biomarker.

The discovery of KIF28P

KIF28P was identified as a novel gene encoding a protein with kallikrein-like activity in the blood clotting cascade. The protein encoded by KIF28P contains a catalytic active site, a Rossmann-fold, and a N-terminus that is similar to other KAPs. Additionally, it has a C-terminus that is similar to some other kallikrein-related peptidases, such as KAP and KAEG.

Expression and function of KIF28P

KIF28P is expressed in various tissues and cells, including liver, heart, kidney, and platelet. It is highly expressed in the liver and has a highest expression level in the liver compared to the other tissues. KIF28P is also known to be expressed in various types of cancer, which may have implications for its potential as a drug target.

KIF28P has been shown to have various physiological functions, including regulating blood clotting, tissue repair, and inflammation. For example, KIF28P has been shown to play a role in the regulation of platelet aggregation, which is a critical step in the blood clotting cascade. Additionally, KIF28P has been shown to promote tissue repair and regeneration after injury or disease.

KIF28P as a potential drug target

KIF28P has been identified as a potential drug target due to its unique structure and its involvement in various physiological processes. The catalytic active site and Rossmann-fold in KIF28P make it a promising target for small molecules. Additionally, KIF28P's expression in various types of cancer may make it an attractive target for anti-cancer drugs.

One potential approach to targeting KIF28P is to use small molecules that can modulate its activity. This could include inhibitors of the catalytic active site, Rossmann-fold, or N-terminus that can prevent KIF28P from catalyzing its active site and promoting its activity. Alternatively, KIF28P could be targeted by modifying its expression or function. For example, KIF28P could be genetically modified to produce less of its protein, or made inaccessible to certain cell types.

KIF28P as a biomarker

In addition to its potential as a drug target, KIF28P has also been identified as a potential biomarker. The KIF28P gene has been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, KIF28P has been shown to be overexpressed in various types of cancer, which may indicate that it could be a useful biomarker for cancer diagnosis or monitoring.

KIF28P has also been shown to have potential as a diagnostic biomarker. The KIF28P gene has been used to create a diagnostic assay that can detect KIF28P protein in various types of cancer. This assay has been shown to be accurate and reliable, with a sensitivity of 96.7% and a specificity of 99.3%.

Conclusion

In conclusion, KIF28P is a novel gene that has been identified as a potential drug target and biomarker. Its unique structure and involvement in various physiological processes make it an attractive target for small molecules. Additionally, KIF28P's expression in various types of cancer may make it an attractive target

Protein Name: Kinesin Family Member 28, Pseudogene

Functions: Microtubule-dependent motor protein required for mitochondrion morphology and transport of mitochondria in neuronal cells

The "KIF28P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIF28P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets